Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus S-1 for neoadjuvant treatment and postoperative S-1 maintenance in colorectal cancer
ChiCTR1800014374Phase 4Not yet recruiting
- Sponsor
- Guangyuan Central Hospital
- Start
- Feb 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and tegafur in colorectal cancer (CRC), sponsored by Guangyuan Central Hospital. Primary endpoints: Total resection rate (R0/R1/R2), Two-year disease-free survival rate and 2 more. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800014374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014374.